The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.42
Bid: 17.42
Ask: 18.08
Change: 0.14 (0.80%)
Spread: 0.66 (3.789%)
Open: 17.42
High: 17.42
Low: 17.42
Prev. Close: 17.61
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of Placing

15 Oct 2013 16:00

RNS Number : 5821Q
Nanoco Group PLC
15 October 2013
 

15 October 2013

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, THE REPUBLIC OF IRELAND OR SOUTH AFRICA OR ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL

 

Nanoco Group plc

 

Completion of Placing

 

Introduction

 

Pursuant to the announcement earlier today, Nanoco Group plc (AIM: NANO) ("Nanoco", the "Company" or the "Group") is pleased to announce that it has successfully placed a total of 6,369,427 new ordinary shares of 10 pence each (the "Placing") at a price of 157 pence per share on a non pre-emptive basis raising total gross proceeds of approximately £10 million. Application has been made for the Placing shares to be admitted to trading on AIM and it is expected that the admission will take place at 8:00 a.m. on 21 October 2013 ("Admission").

 

Further details of the Placing are set out in the announcement released earlier today.

 

Canaccord Genuity Limited ("Canaccord") and Liberum Capital Limited ("Liberum") acted as Joint Bookrunners in relation to the Placing.

 

Following Admission, it is expected that Nanoco will have 216,530,436 Ordinary Shares in issue. The Company holds 12,222 Ordinary Shares in treasury; therefore the total number of voting rights in the Company is 216,518,214. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA Disclosure and Transparency Rules.

 

Commenting on the completion of the Placing, Nanoco Group plc Chief Executive Officer Michael Edelman said: 

 

"We are delighted by the support from new and existing institutional investors in this Placing and I would particularly like to welcome new investors to our shareholder register. We will remain focused on careful cash control as we deploy the proceeds of this fundraising to accelerate the commercialisation of our technology."

 

 

For further information

Nanoco

+ 44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

Colin White, Chief Financial Officer

Canaccord Genuity Limited - Nomad and Joint Broker

+44 (0) 20 7523 8000

Corporate Broking

Simon Bridges

Cameron Duncan

Equity Capital Markets

Tim Redfern

Kit Stephenson

Liberum Capital Limited - Joint Broker

+44 (0) 20 3100 2222

Simon Atkinson

Richard Bootle

Buchanan

+ 44 (0) 20 7466 5000

Mark Court

Fiona Henson

Sophie Cowles

 

About Nanoco:

 

Nanoco is a world leader in the development and production of cadmium-free quantum dots for use in multiple applications including LCD displays, lighting and solar cells. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and business development offices in the USA, Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco began trading on the AIM market of the London Stock Exchange in May 2009 under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

 

IMPORTANT NOTICE

 

This announcement has been issued by, and is the sole responsibility of, Nanoco. No person has been authorised to give any information or to make any representations other than those contained in this announcement and, if given or made, such information or representations must not be relied on as having been authorised by the Company, Canaccord Genuity Limited or Liberum Capital Limited.

 

This announcement is for information purposes only and does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities of the Company in any jurisdiction and should not be relied upon in connection with any decision to subscribe for or acquire any such securities. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. Members of the public will not be eligible to take part in any placement of the securities of Nanoco described herein.

 

Any securities of the Company described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, transferred or delivered, directly or indirectly, in, into or within the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act. Furthermore, the securities of the Company described in this announcement have not been and will not be registered under the applicable laws of any of Canada, Australia, New Zealand, Japan, the Republic of Ireland or South Africa and, consequently, may not be offered or sold to any national, resident or citizen thereof.

 

The distribution of this announcement, in whole or in part, directly or directly, in or into jurisdictions other than the United Kingdom may be restricted by law and therefore any person who is subject to the laws of any jurisdiction other than the United Kingdom should inform themselves about, and observe such restrictions. Any failure to comply with the applicable restrictions may constitute a violation of the securities laws of any such jurisdiction. Subject to certain exceptions, this document is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States, Canada, Australia, New Zealand, Japan, the Republic of Ireland, South Africa or any jurisdiction where to do so might constitute a violation of local securities laws or regulations.

 

No prospectus or offering document has been or will be prepared in connection with the Placing. Any investment decision to buy securities in the Placing must be made solely on the basis of publicly available information. Such information is not the responsibility of, and has not been independently verified by, Canaccord or Liberum or any of their respective affiliates.

 

This announcement and any offer of securities to which it relates are only addressed to and directed at persons who: (A) if in the United Kingdom, are persons who are (i) "qualified investors" as defined in section 86(7) of the Financial Services and Markets Act 2000 and who are investment professionals falling within Article 19(1) or Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth companies, unincorporated associations or partnerships or trustees of high value trusts as described in Article 49(2)(a) to (d) of the Order or (iii) other persons to whom it may otherwise lawfully be communicated; (B) if in a Member State of the European Economic Area, are persons who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (which means Directive 2003/71/EC and includes any relevant implementing directive measure in any Member State), and/or (C) in the United States, "accredited investors" as defined in Rule 501 of the U.S. Securities Act, (all such persons referred to in (A),(B) and (C) together being "Relevant Persons"). The information regarding the Placing set out in this announcement must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

 

Canaccord Genuity Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for the Company as Nominated Adviser and broker to Nanoco for the purposes of the AIM Rules for Companies and the AIM Rules for Nominated Advisers in connection with any placement of the securities of Nanoco described herein and admission of such securities and is not acting for, and will not be responsible to, any person other than Nanoco for providing the protections afforded to customers of Canaccord Genuity Limited or for advising any other person on any transaction or arrangement referred to in this announcement.

 

Liberum Capital Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for the Company as broker in connection with any placement of the securities of Nanoco described herein and admission of such securities and is not acting for, and will not be responsible to, any person other than Nanoco for providing the protections afforded to customers of Liberum Capital Limited or for advising any other person on any transaction or arrangement referred to in this announcement.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKMMMGDKNGFZM
Date   Source Headline
16th Jul 20214:41 pmRNSSecond Price Monitoring Extn
16th Jul 20214:35 pmRNSPrice Monitoring Extension
15th Jul 20217:00 amRNSNon-dilutive loan note subscription
5th Jul 20217:30 amRNSDevelopment Agreement
28th Jun 20217:00 amRNSLitigation update and non-dilutive debt facility
10th Jun 202111:33 amRNSBlocklisting Six-Monthly Return
24th May 202112:20 pmRNSHolding(s) in Company
20th May 20217:00 amRNSLitigation Update
13th May 20217:00 amRNSProject Extension
12th May 20217:00 amRNSLitigation Update
6th May 20213:28 pmRNSHolding(s) in Company
30th Mar 20217:00 amRNSInterim Results
29th Mar 20217:00 amRNSLitigation Update
26th Mar 20214:41 pmRNSSecond Price Monitoring Extn
26th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 20213:36 pmRNSAmendment to Executive Director Service Terms
16th Mar 20212:30 pmRNSNotice of Results
10th Feb 20214:40 pmRNSSecond Price Monitoring Extn
10th Feb 20214:35 pmRNSPrice Monitoring Extension
25th Jan 20214:41 pmRNSSecond Price Monitoring Extn
25th Jan 20214:35 pmRNSPrice Monitoring Extension
29th Dec 20204:41 pmRNSSecond Price Monitoring Extn
29th Dec 20204:36 pmRNSPrice Monitoring Extension
21st Dec 20207:00 amRNSDirector/PDMR Shareholding
11th Dec 202011:40 amRNSBlocklisting Six-Monthly Return
3rd Dec 202012:10 pmRNSResult of AGM
3rd Dec 20207:00 amRNSAGM Statement
25th Nov 20207:00 amRNSGrant Funding Award for Life Sciences Project
17th Nov 20205:50 pmRNS2020 Annual Report and Notice of AGM
22nd Oct 20204:40 pmRNSSecond Price Monitoring Extn
22nd Oct 20204:35 pmRNSPrice Monitoring Extension
21st Oct 20203:16 pmRNSDirector/PDMR Shareholding
13th Oct 20207:00 amRNSPreliminary Results
7th Oct 20207:00 amRNSNotice of Results
25th Sep 20204:36 pmRNSPrice Monitoring Extension
1st Sep 20207:00 amRNSDirectorate Changes
21st Jul 202011:25 amRNSHolding(s) in Company
20th Jul 202012:35 pmRNSHolding(s) in Company
16th Jul 20202:15 pmRNSDirector/PDMR Shareholding
16th Jul 20207:00 amRNSResult of Fund Raise
15th Jul 20205:20 pmRNSPrimaryBid.com Offer
15th Jul 20205:17 pmRNSTrading Update and Proposed Fundraising
14th Jul 20209:55 amRNSHolding(s) in Company
13th Jul 20207:00 amRNSLitigation Funding Agreement
2nd Jul 20204:40 pmRNSSecond Price Monitoring Extn
2nd Jul 20204:36 pmRNSPrice Monitoring Extension
30th Jun 202010:06 amRNSHolding(s) in Company
9th Jun 20207:00 amRNSBlocklisting Six-Monthly Return
5th Jun 20204:41 pmRNSSecond Price Monitoring Extn
5th Jun 20204:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.